Furzer, J., Gupta, S., Nathan, P. C., Schechter, T., Pole, J. D., Krueger, J., & Pechlivanoglou, P. (2020). Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada. JAMA Oncol.
Citação norma ChicagoFurzer, Jill, Sumit Gupta, Paul C. Nathan, Tal Schechter, Jason D. Pole, Joerg Krueger, and Petros Pechlivanoglou. "Cost-effectiveness of Tisagenlecleucel Vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada." JAMA Oncol 2020.
Citação norma MLAFurzer, Jill, et al. "Cost-effectiveness of Tisagenlecleucel Vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada." JAMA Oncol 2020.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.